Rapid cognitive decline in a patient with chronic lymphocytic leukaemia: a case report
ConclusionPML remains a rare complication of ofatumumab treatment. Nevertheless, clinicians should maintain a certain level of suspicion for this risk, especially in the context of patients presenting with clinical syndromes of encephalopathy and focal neurologic deficits. Furthermore, research to better our understanding of the manifold links between B-cell function and JCV regulation could provide valuable information for use in the future prevention and treatment of PML.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
More News: Acute Leukemia | Biochemistry | Brain | Cancer & Oncology | Chemistry | Chronic Leukemia | Chronic Lymphocytic Leukemia | General Medicine | Leukemia | MRI Scan | Neurology | Palliative | Palliative Care | Rituxan | Tysabri